Skip to main content

Table 1 Summary of the clinico-pathological data of the colorectal cancer patient cohort

From: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Case ID# Gender Age Location Date resected Tissue specimens Sample ID # T Number Histo-type G MSI CIMP Treatment
1 m 71 Colon right 03/04 NO 1        Ardalan
03/04 PT 2 pT3 pN1 (3/20) NOS G3 neg neg
05/04 synM[HEP] 3       
04/08 metM[PUL] 5       
2 f 65 Rectum 12/09 NO 6        Not available
12/09 PT 7 pT3 pN1 (3/20) NOS G3 neg neg
02/10 synM[HEP] 8       
04/10 synM[PUL] 9       
06/10 synM[PUL] 11       
3 m 51 Colon left 09/07 NO 13        FOLFOXIRI, FOLFOXIRI/Bevacizumab, Xeloda/Bevacizumab, CAPIRI, Mitomycin, FOLFOX
09/07 PT 14 pT3 pN1 (1/14) NOS G2 neg neg
05/08 metM[HEP] 15       
09/08 metM[PUL] 16       
09/08 metM[PUL] 17       
11/08 metM[PUL] 18       
4 m 64 Rectuma 04/05 NO 21        FOLFOX, 5-FU/Mitomycin, FOLFIRI
04/05 PT 22 ypT3 ypN2 (5/24) NOS G2 neg neg
04/05 syn[HEP] 25       
11/05 metM[HEP] 23       
02/06 metM[PUL] 49       
5 f 57 Colon left 10/12 NO 28        3x FOLFOXIRI/Bevacizumab
10/12 PT 50 pT4a pN2a (6/35) NOS G2 neg neg
10/12 synM[HEP] 29       
04/13 synM[PUL] 32       
05/13 synM[PUL] 32       
6 f 67 Colon left 03/06 NO 34        3x FOLFIRI/Bevacizumab, FOLFOX
03/06 PT 36 pT3 pN2 (4/16) NOS G2 neg pos
04/08 metM[HEP] 38       
05/10 metM[PUL] 39       
7 f 35 Colon left 07/07 NO 40        FOLFOX4
07/07 PT 41 pT4 N1 (2/31) NOS G2 neg neg
07/07 synM[HEP] 42       
07/08 metM[HEP] 44       
12/08 metM[HEP] 45       
07/11 metM[PUL] 47       
8 f 50 Colon left 07/10 NO 54        FOLFOXIRI, FOLFOXIRI/Bevacizumab
07/10 PT 55 pT3 pN1 (1/14) NOS G2 neg neg
08/10 synM[HEP] 56       
10/10 synM[PUL] 58       
07/11 metM[PUL] 59       
9 f 62 Colon left 07/05 NO 61        Xeloda
07/05 PT 62 pT3 pN1 (2/12) NOS G2 neg neg
09/5 synM[HEP] 63       
11/08 metM[PUL] 64       
01/09 metM[PUL] 66       
02/13 metM[PUL] 68       
10 m 51 Rectuma 01/04 NO 70        RCTx
01/04 PT 71 ypT3 ypN0 (0/15) NOS G2 neg neg
10/05 metM[HEP] 73       
02/09 metM[PUL] 74       
11 f 44 Rectuma 12/07 NO 75        FOLFIRI/Bevacizumab
12/07 PT 76 ypT2 ypN0 (0/4) NOS G2 neg neg
07/07 synM[HEP] 77       
11/08 metM[PUL] 78       
07/10 metM[PUL] 80       
12 m 48 Rectuma 01/11 NO 87        RCTx, Xeloda, FOLFIRI/Bevacizumab, FOLFIRI
01/11 PT 88 ypT3 ypN1b (2/5) NOS G2 neg neg
04/11 synM[HEP] 89       
04/12 metM[PUL] 91       
05/12 metM[PUL] 92       
13 m 61 Colon left 09/03 NO 94        Not available
09/03 PT 95 pT3 pN1 (2/22) Muc. G3 neg pos
09/03 synM[HEP] 97       
07/03 synM[PUL] 98       
07/03 synM[PUL] 99       
14 m 67 Colon right 02/14 NO 100        2x FOLFOXIRI/Bevacizumab, FOLFIRI/Bevacizumab
02/14 PT 101 pT4b pN0 (0/28) NOS G2 neg neg
02/14 synM[HEP] 102       
02/14 synM[HEP] 103       
04/14 synM[PUL] 104       
  1. No normal colonic epithelium, PT primary tumour, synM[HEP] synchronous liver metastasis, metM[HEP] metachronous liver metastasis, synM[PUL] synchronous lung metastasis, metM[PUL] metachronous lung metastasis
  2. arectal carcinoma patients received neoadjuvant treatment. The primary anatomic site for colon carcinomas is given with “location”